Catalog
All Compounds
Every compound independently verified via HPLC-MS. Certificate of Analysis available for each batch.
AX-01 — ≥99% purity
Recovery I
A cornerstone recovery compound with over two decades of published preclinical data demonstrating pathway-specific activity in tissue repair cascades. Peer-reviewed models show upregulation of growth factor expression, angiogenic signaling, and nitric oxide-mediated vasodilation — key mechanisms in accelerating cellular regeneration across multiple tissue types.
AX-02 — ≥98.5% purity
Recovery II
An advanced recovery compound with published data on thymosin-family signaling, promoting actin sequestration and extracellular matrix remodeling. Preclinical models demonstrate synergistic tissue repair when combined with AX-01, with researchers observing enhanced collagen deposition and accelerated wound closure through complementary inflammatory modulation pathways.
AX-03 — ≥99% purity
Performance I
A growth-factor secretagogue with extensive published data on pulsatile endogenous release stimulation via the growth hormone secretagogue receptor (GHS-R1a). Preclinical models demonstrate sustained IGF-1 elevation without desensitization when administered in physiologically relevant intervals, making it a staple in performance-oriented research protocols.
AX-04 — ≥98% purity
Performance II
A selective compound targeting androgen receptor-mediated anabolic pathways with tissue-specific binding affinity documented in peer-reviewed pharmacological studies. Preclinical data indicates favorable anabolic-to-androgenic ratios, with researchers citing its utility in lean mass and bone density investigation protocols.
AX-05 — ≥99% purity
Longevity I
A telomerase-activating compound under active investigation in cellular senescence research. Published preclinical data demonstrates pineal-mediated modulation of circadian gene expression, melatonin synthesis restoration, and telomere elongation in dividing cell populations — positioning it as a leading candidate in age-related pathway research.
AX-06 — ≥99% purity
Longevity II
A NAD+ precursor compound with peer-reviewed data on mitochondrial biogenesis through PGC-1alpha signaling and SIRT1/SIRT3 activation. Published models demonstrate improved mitochondrial membrane potential, enhanced ATP production efficiency, and downstream effects on cellular energy metabolism relevant to longevity research.
AX-07 — ≥98.5% purity
Cognitive I
A nootropic compound with published preclinical data on BDNF upregulation, TrkB receptor agonism, and enhanced long-term potentiation in hippocampal models. Researchers cite its role in synaptic plasticity, neuronal survival signaling, and anxiolytic activity without sedation — a rare profile in cognitive research compounds.
AX-08 — ≥99% purity
Metabolic I
A dual-agonist compound targeting GLP-1 and GIP receptor pathways simultaneously, with published preclinical data on insulin sensitization, hepatic lipid oxidation, and appetite regulation via hypothalamic signaling. Clinical experts regard multi-receptor agonism as the frontier of metabolic research due to its non-linear efficacy profile.
PRO-01 — ≥98.5% purity
Recovery Stack
A curated research bundle combining AX-01 and AX-02 for multi-pathway tissue repair investigation. Published preclinical models demonstrate that pairing angiogenic and anti-inflammatory signaling compounds produces synergistic collagen synthesis rates exceeding either compound alone — a finding consistently reported across leading practitioners in recovery research.
PRO-02 — ≥98.5% purity
Performance Stack
A premium research bundle pairing AX-03 and AX-04 for simultaneous investigation of endogenous growth factor secretion and tissue-selective anabolic signaling. Researchers report that combining secretagogue and receptor-targeted compounds enables multi-axis performance modeling not achievable with single-compound protocols.